The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.


This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
23 December 2021

“Darnitsa” was presented at the international pharmaceutical exhibition in Milan

23 December 2021

Pharmaceutical company “Darnitsa” took part in a specialized international exhibition CPhI Worldwide 2021 (Convention of Pharmaceutical Ingredients) in Milan, which brings together leaders of the pharmaceutical market from around the world. Each year the event is held in different countries, but its mission remains the same: it is an exhibition of pharmaceutical ingredients and intermediate products, during which manufacturers present themselves, establish new business relationships and strengthen existing ones.

Milan was chosen as CPhI Worldwide 2021 because it is considered the Italian capital of life sciences and Italy itself is the largest manufacturer and exporter of active pharmaceutical ingredients (API) in Europe. Pharmaceutical manufacturers who fully meet international standards were invited to participate in the event.

“Darnitsa” has been certified for compliance with Good Manufacturing Practice (GMP) since 2002. It is a mandatory certification standard for pharmaceutical manufacturing in Europe, recognized worldwide. Today GMP certificate allows “Darnitsa” export medicines to 15 countries of EU, CIS, Middle East and East Asia, and work on entering new markets, in particular Australia and Israel. Currently, the annual export growth rate is around 30%

At present “Darnitsa” belongs to the top-1000 pharmaceutical companies in the world and owns a portfolio of 177 brands and 358 names of finished medicines. The company has invested US 3.5 million in new products development. Over the last three years, it has completed 11 bioequivalence studies for treatment of heart and central nervous system diseases, the majority of which took place in the EU. The studies have demonstrated the therapeutic equivalence and safety of generic medicines.

“We plan to expand the geography of our products exports that is why participation in such exhibitions is strategically important for us. In October we hosted our export partners in Kiev, and at CPhI Worldwide 2021 in Milan we worked on new partnerships,” – stated Iryna Radchenko, Export Director of pharmaceutical company “Darnitsa”.

CPhI Worldwide 2021 was held in November in a hybrid format: an offline exhibition and conference was combined with online sessions. It is worth noting that this time the event organisers rejected paper catalogues, guides, magazines and badges, offering participants a special mobile application with all the necessary information instead of them. For “Darnitsa”, which is actively implementing electronic document management, including digital files of medicines, this is additional proof that the company is moving in the right direction.


PJSC Pharmaceutical Company “Darnitsa” was founded in 1930. Since 1998, “Darnitsa” has been Ukraine’s leader in the production of medicines in volume terms. The strategic areas of portfolio development are cardiology, neurology and pain management. During 2015-2020, “Darnitsa” has launched 50 pharmaceutical brands on the market.

Specialized edition for medical institutions and doctors.